We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Diagnostic Microchip Inserted Under Skin Can Detect COVID-19

By LabMedica International staff writers
Posted on 14 Apr 2021
Print article
Image: Diagnostic Microchip Inserted Under Skin Can Detect COVID-19 (Photo courtesy of DARPA)
Image: Diagnostic Microchip Inserted Under Skin Can Detect COVID-19 (Photo courtesy of DARPA)
Researchers have created a microchip that can detect COVID-19 when inserted under the skin.

The implantable microchip developed by medical researchers at the US Pentagon’s Defense Advanced Research Projects Agency (DARPA; Arlington, VA, USA) can monitor the human body for signs of the SARS-CoV-2 virus. Details of the revolutionary technology were shared on the 60 Minutes Show by Matthew Hepburn, an infectious disease physician and retired Army colonel who is heading DARPA’s response to the pandemic.

Hepburn told CBS that the microchip, embedded in a tissue-like gel, would continuously test the chip recipient’s blood for presence of the coronavirus. Upon detecting COVID-19, the chip would alert the patient to conduct a self-administered rapid blood test to confirm the positive result. According to Hepburn, DARPA had also developed a filter to remove the SARS-CoV-2 virus from the blood through a dialysis machine. The filter had been approved by the US Food and Drug Administration (FDA) and had already been used on 300 patients. Additionally, Hepburn compared the diagnostic microchip to a car’s “Check engine” alert and assured that DARPA’s chip would neither “track your every move” nor be administered via vaccines.

“It’s a sensor,” Hepburn told CBS. “That tiny green thing in there, you put it underneath your skin and what that tells you is that there are chemical reactions going on inside the body and that signal means you are going to have symptoms tomorrow. We can have that information in three to five minutes. As you truncate that time, as you diagnose and treat, what you do is you stop the infection in its tracks.”

Related Links:
Defense Advanced Research Projects Agency (DARPA)

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
SARS-CoV-2 RT-PCR Assay
Reliance SARS-CoV-2 RT-PCR Assay Kit

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The ePlex system has been rebranded as the cobas eplex system (Photo courtesy of Roche)

Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases

GenMark Diagnostics (Carlsbad, CA, USA), a member of the Roche Group (Basel, Switzerland), has rebranded its ePlex® system as the cobas eplex system. This rebranding under the globally renowned cobas name... Read more

Pathology

view channel
Image: The revolutionary autonomous blood draw technology is witnessing growing demands (Photo courtesy of Vitestro)

Robotic Blood Drawing Device to Revolutionize Sample Collection for Diagnostic Testing

Blood drawing is performed billions of times each year worldwide, playing a critical role in diagnostic procedures. Despite its importance, clinical laboratories are dealing with significant staff shortages,... Read more